Sun Signs $485m Settlement Deal To Close Out Ranbaxy Antitrust Case
Indian Firm’s Ranbaxy Unit Accused Of Submitting Substandard ANDAs
Executive Summary
India’s Sun Pharma is set to hand over almost half-a-billion dollars to resolve claims that its Ranbaxy unit schemed to delay the launch of generic versions of three popular prescription drugs. The firm has denied all allegations as part of the deal, which must be signed off by a US district court.